Overview
- Attorney General Ken Paxton asked a state judge on Thursday to block a roughly $398–$400 million dividend Kenvue has scheduled for Nov. 26.
- Texas argues the payout would be a fraudulent transfer given potential multibillion-dollar liabilities tied to alleged Tylenol harms and international talc litigation.
- Paxton also seeks to bar Kenvue from telling Texans that Tylenol is safe for pregnant women and young children while the case proceeds.
- Kenvue says the allegations lack legal merit and scientific support, noting disputes over whether studies show a causal link.
- The requested injunction adds uncertainty to Kimberly‑Clark’s planned Kenvue acquisition reported around $40 billion, with Kenvue shares trading well below the offer price.